Drugs / monovalent HBV vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03567382 | Sep 2018 → Mar 2020 | hepatitis B virus infection, infectious embryofetopathy | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | monovalent HBV vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03567382 ↗ |
| Known as | Euvax-B Pediatric | “All HBV-exposed infants received a birth-dose of monovalent HBV vaccine (Euvax-B Pediatric: Sanofi Pasteur, Seoul, South Korea; 0·5 mL) within 24 h of life.” PMID 34416175 ↗ Aug 2021 |
| Modality | Vaccine | “birth-dose of monovalent HBV vaccine” PMID 34416175 ↗ Aug 2021 |